Accessibility Menu
Trafalgar International logo

Trafalgar International(OTC) GCAN

Market Cap$248.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-97%
1 Year-44%
1 Month-7%
$0.25
-24.68%
-0.08Today
Trafalgar International last closing stock price
MetricPriceDate
Last closeUSD 0.252026-08-19
Trafalgar International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.78%USD 0.232026-08-12
1 month-7.33%USD 0.272026-07-20
3 month+41.27%USD 0.182026-05-21
Year to date+233.73%USD 0.082025-12-31
1 year-44.38%USD 0.452025-08-19
3 year-76.16%USD 1.052023-08-18
5 year-96.97%USD 8.252021-08-20
Since inception-99.88%USD 209.992018-09-18

Trafalgar International Financials at a Glance

Market Cap

$248.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$879.66K

EPS (TTM)

$0.89

P/E Ratio

0.28

Dividend

$0.00

Beta (Volatility)

-0.25 (Low)

Price

$0.25

Volume

26

Open

$0.34

Previous Close

$0.25

Daily Range

$0.23 - $0.34

52-Week Range

$0.04 - $0.67

Estimated Earnings Date

Mar 31, 2023

GCAN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Trafalgar International

Greater Cannabis develops therapies using cannabis compounds for brain-related disorders. Its oral patch delivers medicine through the mouth lining. These products aim to help people with conditions like autism or Parkinson’s disease.

Products and Services

  • Cannabinoid Therapeutics: Treatments using cannabis-derived compounds for neuropsychiatric disorders; 0% of revenue in 2025.
  • Oral Transmucosal Patch: A patch placed inside the mouth for medicine absorption; 0% of revenue in 2025.
  • Licensed Therapies: Exclusive rights to develop and sell a cannabinoid therapy from Shaare Zedek Scientific for brain disorders; 0% of revenue in 2025.
  • Research and Development: Ongoing work on new cannabis-based drug formulas; no direct revenue contribution in 2025.

Growth and Expansion

  • Signed exclusive license and joint R&D agreement with Shaare Zedek Scientific in 2021.
  • Shifted focus from e-commerce to drug development in 2018.
  • Completed preclinical studies in February 2024 and received approval for Phase II clinical trials in July 2023.
  • Implemented a 1-for-1,500 reverse stock split in October 2025.
  • Created Series B Convertible Preferred Stock for CEO voting control in 2025.

What Makes Greater Cannabis Stand Out

The company uses a unique oral patch to deliver cannabis-based drugs without swallowing pills. Its exclusive partnership with a major Israeli medical center gives access to novel therapies. Operations are lean, with only one full-time employee and a focus on research.

Five Things You Need to Know

  • No revenue reported for 2025, 2024, or 2023.
  • Net loss was $331,612 in 2025, up 85.2% from 2024.
  • Cash at year-end 2025 was $815, down from $57,368 in 2024.
  • Negative working capital of $741,649 as of December 31, 2025.
  • Auditor raised substantial doubt about the company’s ability to continue operating.

Bottom Line

Greater Cannabis has shifted to drug development but faces ongoing financial challenges. Its future depends on securing funding and advancing clinical trials.

AI Generated • Apr 16, 2026

Industry

Capital Markets

Sector

Financials

Employees

1

CEO

Aitan Zacharin

Website

www.gcanrx.com

Headquarters

Baltimore, MD 21209, US

GCAN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-133.43%

Return on Capital

N/A

Return on Assets

792486.49%

Earnings Yield

3.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$248.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

994.40K

Volume

26

Avg. Volume

3.69K

Financials (TTM)

Gross Profit

$417.00

Operating Income

-$136.15K

EBITDA

-$50.39K

Operating Cash Flow

-$40.70K

Capital Expenditure

$0.00

Free Cash Flow

-$40.70K

Cash & ST Invst.

$111.00

Total Debt

$0.00

Trafalgar International Performance Analysis

Trafalgar International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Trafalgar International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Trafalgar International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.92-50.4%
20232023-12-31USD -0.38-59.0%
20242024-12-31USD -0.33-12.0%
20252025-12-31USD -0.4021.8%
Trafalgar International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-13233.3%
Q42025-12-31201.0%
Q12026-03-31-100.0%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$248.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$248.90K

N/A

Employees

1

N/A

Net Income

$611.38K

+256.4%

EBITDA

-$11.56K

+94.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$111.00

-99.6%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

7924.86%

N/A

Return on Invested Capital

11.23%

N/A

Free Cash Flow

-$6.83K

+65.0%

Operating Cash Flow

-$6.83K

+65.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GREHGreen Rain Energy Holdings Inc.
$0.01-0.10%
BBBTBlack Bird Biotech, Inc.
$0.00+0.00%
CANLCannLabs, Inc.
$0.00+0.00%
SETOSETO Holdings, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$41.20+0.06%
MSTRStrategy
$112.39+0.08%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.25-0.02%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$122.21+0.01%

Questions About GCAN

What is the current price of Trafalgar International?

Trafalgar International is trading at $0.25 per share.

What is the 52-week range for Trafalgar International?

Over the past 52 weeks, Trafalgar International has traded between $0.04 and $0.67.

How much debt does Trafalgar International have?

As of the most recent reporting period, Trafalgar International reported total debt of $0.00.

How much cash does Trafalgar International have on hand?

Trafalgar International reported $111.00 in cash and cash equivalents in its most recent financial results.

What is Trafalgar International’s dividend yield?

Trafalgar International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services